These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8341214)

  • 1. Increased risk of cardiac dysfunction after anthracyclines in girls.
    Silber JH; Jakacki RI; Larsen RL; Goldwein JW; Barber G
    Med Pediatr Oncol; 1993; 21(7):477-9. PubMed ID: 8341214
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiotoxicity of anthracyclines. Apropos of 12 pediatric cases].
    Favrot MC; Pouyau G; Souillet G; Philip T; Bozzio A; Philippe N
    Pediatrie; 1981 Sep; 36(6):437-50. PubMed ID: 6947199
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
    Ferrans VJ
    Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of anthracycline antineoplastic drugs--Clinicopathological and experimental studies.
    Suzuki T; Kanda H; Kawai Y; Tominaga K; Murata K
    Jpn Circ J; 1979 Nov; 43(11):1000-8. PubMed ID: 522231
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiotoxicity in children treated with anthracyclines: the role of M-mode echocardiography.
    Galli MA; Conter V; Zanetto F; Jankovic M; Ferrari L; Baio G; Masera G
    Haematologica; 1987; 72(4):347-50. PubMed ID: 3117636
    [No Abstract]   [Full Text] [Related]  

  • 6. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
    Hutchinson RJ; Bailey C; Wood D; Donaldson MH
    Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of cardiac dysfunction after anthracyclines in girls.
    Bu'Lock FA; Martin RP; Mott MG
    Med Pediatr Oncol; 1995 Feb; 24(2):143-4. PubMed ID: 7990765
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
    Bristow MR; Billingham ME; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Frequency analysis of the QRS complex: a new method of detecting development of myocardial damage after anthracycline cytostatics].
    Mladosievicova B; Foltinova A; Paulovic P; Petrasova H; Hulin I
    Bratisl Lek Listy; 2000; 101(7):409-11. PubMed ID: 11059111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Control of cardiac function during therapy with doxorubicin and other anthracyclines].
    Grille W; Johnsen K; Kolenda KD; Schöttler M; Löffler H
    Dtsch Med Wochenschr; 1985 Jul; 110(28-29):1134-7. PubMed ID: 3859399
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening.
    Jakacki RI; Larsen RL; Barber G; Heyman S; Fridman M; Silber JH
    Cancer; 1993 Nov; 72(9):2739-45. PubMed ID: 8402498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
    Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
    Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation.
    Pihkala J; Saarinen UM; Lundström U; Virtanen K; Virkola K; Siimes MA; Pesonen E
    Eur J Cancer; 1996 Jan; 32A(1):97-103. PubMed ID: 8695252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis].
    Safonova SA; Gershanovich ML; Punanov IuA
    Vopr Onkol; 2006; 52(5):590-2. PubMed ID: 17168373
    [No Abstract]   [Full Text] [Related]  

  • 15. Prechemotherapy cardiac assessment.
    Moore S
    Oncol Nurs Forum; 2009 Sep; 36(5):503-6. PubMed ID: 19726391
    [No Abstract]   [Full Text] [Related]  

  • 16. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
    Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
    J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Increased risk of cardiac dysfunction after anthracyclines in girls".
    Silber JH; Barber G
    Med Pediatr Oncol; 1995 Aug; 25(2):130-1. PubMed ID: 7603400
    [No Abstract]   [Full Text] [Related]  

  • 18. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?
    van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP
    Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiac safety of liposomal anthracyclines.
    Batist G
    Cardiovasc Toxicol; 2007; 7(2):72-4. PubMed ID: 17652807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
    Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.